Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Relacorilant: First Approval.

Drugs·2026

Same author

Rovadicitinib: First Approval.

Drugs·2026

Same author

Sonrotoclax: First Approval.

Drugs·2026

Same author

Copper Histidinate: Pediatric First Approval.

Paediatric drugs·2026

Same author

Correction: Avutometinib and Defactinib: First Approval.

Drugs·2026

Same author

Lerodalcibep: First Approval.

Drugs·2026

Search research articles

Related Experiment Video

Updated: Jul 25, 2025

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Published on: November 11, 2022

Efbemalenograstim Alfa: First Approval.

Hannah A Blair¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|June 27, 2023

Summary

Efbemalenograstim alfa (Ryzneuta) is a new drug approved in China to manage chemotherapy-induced neutropenia. It helps reduce infection risk in cancer patients undergoing myelosuppressive treatment.

Area of Science:

Oncology
Pharmacology
Biotechnology

Background:

Chemotherapy-induced neutropenia (CIN) is a significant side effect of cancer treatment.
Febrile neutropenia increases infection risk and can lead to treatment delays.
Novel therapeutic agents are needed to manage CIN effectively.

Purpose of the Study:

To summarize the development milestones of efbemalenograstim alfa.
To highlight the regulatory approval of efbemalenograstim alfa for CIN management.
To provide an overview of efbemalenograstim alfa's journey to market.

Main Methods:

Review of efbemalenograstim alfa development data.
Analysis of clinical trial outcomes related to CIN.
Summary of regulatory submission and approval processes.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

Related Experiment Videos

Last Updated: Jul 25, 2025

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Published on: November 11, 2022

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

Main Results:

Efbemalenograstim alfa, a recombinant fusion protein, has been developed for CIN.
Approved in China on May 6, 2023, for reducing infection incidence in CIN patients.
Currently under regulatory review in the EU and USA.

Conclusions:

Efbemalenograstim alfa represents a significant advancement in managing chemotherapy-induced neutropenia.
The drug's approval in China marks a key milestone in its global development.
Further regulatory reviews in the EU and USA are anticipated.